DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Nature-based beverage solutions - Suntory Beverage & Food Europe and BRAIN AG start Joint Development Program


 

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Alliance
B.R.A.I.N. Biotechnology Research And Information Network AG: Nature-based beverage solutions - Suntory Beverage & Food Europe and BRAIN AG start Joint Development Program

26.11.2018 / 08:50
The issuer is solely responsible for the content of this announcement.


Nature-based beverage solutions
Suntory Beverage & Food Europe and BRAIN AG start Joint Development Program

  • Joint efforts to address increasing demands for nature-based ingredients in beverages
  • BRAIN contributes its unique BioArchive resources and screening technologies for future production
  • Suntory provides comprehensive expertise in product development, formulation as well as marketing and sales


Zwingenberg, Germany
Uxbridge, United Kingdom
26 November 2018

The bioeconomy pioneer BRAIN AG and Suntory Beverage & Food Europe (SBFE), the regional division of Suntory Beverage & Food operating in the non-alcoholic beverage business in EMEA through a broad variety of brands, announced today the start of a Joint Development Program to develop new natural beverage solutions for specified product categories of SBFE's portfolio. The joint development activities will address growing demands for new varieties of natural ingredients in beverages.

Suntory Beverage & Food Europe will have worldwide privileged access to the jointly discovered and developed natural matrices for agreed beverage fields. The industry partners have agreed on a time-plan with cost compensation milestone-payments for BRAIN. The partners aim at first product launches within up to three years. BRAIN is meant to finally deliver the nature-based solutions for the production of beverages at SBFE's facilities.

The cooperation partners have agreed to not disclose further financial or content details of the cooperation.

 

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en.
 

About Suntory Beverage & Food Europe

Suntory Beverage & Food Europe, part of Suntory Group is the third largest worldwide drinks company. SBFE is a group of 3800 employees working across four business units in Europe, Africa, Middle East and Caribbean. SBFE owns a large portfolio of soft-drinks brands, answering all consumer expectations. To achieve the mission, revolutionize drinking, our brands cover all segments: still and carbonated fruit-based drinks, tonics, juices, nectars, concentrates and even sports drinks and celebratory drinks for children. Many products have leading positions in their respective national markets. SBFE group's brands are local, unique, with strong individual characters, instantly recognized and loved by our consumers. The consumers are the foundation on which the company is built. Further information is available at www.suntorybeverageandfood-europe.com.

BžRžAžIžN
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
www.brain-biotech.de
 
Media Contact
Thomas Deichmann
Head of Public Relations
Tel.: +49-(0)-6251-9331-72
[email protected]
 
Investor Relations Contact
Dr. Martin Langer
EVP Corporate Development
Tel.: +49-(0)-6251-9331-16
[email protected]
 
Suntory Beverage & Food Europe
2 Longwalk Road, Stockley Park, Uxbridge, UB11 1BA
United Kingdom
www.suntorybeverageandfood-europe.com
 



26.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

750829  26.11.2018 

fncls.ssp?fn=show_t_gif&application_id=750829&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 24,11 27,05 38,56 38,23 38,39 45,51 55,34
EBITDA1,2 -7,70 -6,55 -2,50 -3,88 -2,53 -1,31 -0,83
EBITDA-Marge3 -31,94 -24,21 -6,48 -10,15 -6,59 -2,88
EBIT1,4 -9,37 -9,57 -7,20 -8,23 -6,55 -5,65 -5,48
EBIT-Marge5 -38,86 -35,38 -18,67 -21,53 -17,06 -12,42 -9,90
Jahresüberschuss1 -9,40 -8,37 -11,12 -9,02 -4,68 -6,34 -8,11
Netto-Marge6 -38,99 -30,94 -28,84 -23,59 -12,19 -13,93 -14,66
Cashflow1,7 -5,80 -5,42 -3,38 -4,77 -3,10 -1,49 -4,22
Ergebnis je Aktie8 -0,58 -0,45 -0,61 -0,52 -0,25 -0,30 -0,38
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
BRAIN Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 2,840 Halten 62,05
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
28,40 0,00 0,00 -6,17
KBV KCV KUV EV/EBITDA
2,85 - 1,12 -104,88
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 12.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2024 28.05.2024 29.08.2024 17.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-20,98% -28,50% -22,40% -50,52%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei EQS abrufen


Biotechnologie , 520394 , BNN , XETR:BNN